MediciNova, Inc.
MN-166 (Ibizalast) Phase 2b/3 Clinical Trial in ALS: Final Patient Last Visit Completed for Double‑Blind Treatment Period
In the COMBAT-ALS trial for MN-166 in ALS, the final patient last visit for the double‑blind treatment period has been completed. Top-line data are planned for the end of 2026. No impact on the consolidated results for the year ending December 2026.
Key Figures
- Top-line data publication planned: end of 2026
- Double‑blind treatment period: 12 months
- Open-label period: 6 months
AI要約
Key Points of the News
Announcing that the final patient last visit for MN-166 in the COMBAT-ALS trial targeting ALS has been completed. The primary endpoints include CAFS scores, with top-line data expected to be released by the end of 2026. It is stated that there is no financial impact for the year ending December 2026.
Upcoming Developments and Outlook
Continuing database lock and data analysis, advancing analyses of the double‑blind portion. Attention centers on the company’s pipeline progress as it pursues potential expansion into neurological diseases such as ALS with new therapies.
MediciNova, Inc.
Company overview · Stock price · Financial data · All IR
